Executive Vice President, Chief Medical Officer · Aligos Therapeutics, Inc. (ALGS)

Matthew McClure

FY2023 is the first fiscal year CompBrief holds for Matthew McClure as a named executive officer of Aligos Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$837,724

Salary $481,993Stock awards $0

3rd of 4 named executive officers at Aligos Therapeutics by FY2023 total.

4 named officers on file for Aligos Therapeutics, FY2023

Matthew McClure’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aligos Therapeutics’s whole pay program stands against its peers

  • Aligos Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ALGS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2024 (DEF 14A).

Free

Get Matthew McClure’s full pay file as a PDF — free

More than this page: up to 10 years of Matthew’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Matthew McClure compensation by year

Aligos Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Aligos Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$481,993
Bonus$0
Stock awards$0
Option awards$97,338
Non-equity incentive$219,789
Pension and deferred compensation$0
All other$38,604
Total$837,724

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aligos Therapeutics, Inc. DEF 14A filed April 29, 2024, accession 0001193125-24-122181, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aligos Therapeutics, Inc. filed document, accession 0001193125-24-122181. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option29,709—$1.41
Option23,000—$3.06
Option60,938—$1.34
Option43,001—$0.84
Option49,834—$3.06
Option63,907—$16.18

Per the Outstanding Equity Awards at Fiscal Year-End table in Aligos Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Aligos Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Lawrence BlattPresident and Chief Executive Officer$1,344,458
Leonid BeigelmanFormer President$955,127
Matthew McClure · this pageExecutive Vice President, Chief Medical Officer$837,724
Julian SymonsExecutive Vice President, Chief Scientific Officer$836,319

The full Aligos Therapeutics compensation record

free company brief

This page is one person within Aligos Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aligos Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Matthew McClure's compensation dossier · One-time report. No refunds.